RXRX Recursion Pharma Gross Profit Rate

Official company branding of Recursion Pharmaceuticals, Inc. (RXRX)

The efficiency of Recursion Pharmaceuticals (RXRX) is based on the clinical validation of digital models and the support of tech giants. To train neural networks and produce drugs, the company relies on cloud outsourcing and external contractors. The gross operating margin demonstrates the business's actual return, where the value of -40.00 describes the current level. Currently, the strategy is focused on the active expansion of the AI platform and the advancement of its own molecules through testing.

Recursion Pharmaceuticals (RXRX): Gross Margin from 07/04/2022 to 11/19/2026

Financial and market metric breakdowns for Recursion (RXRX)

- market value and analyst target forecast:
Summary company analysis:Recursion Pharmaceuticals
Core merchandise of recursion.com

Gross margin measures profit generation efficiency by determining the portion of revenue remaining after direct operating costs of product creation. For Recursion Pharmaceuticals (RXRX), this metric reflects the scalability of its AI platform and the impact of milestone payments from Nvidia and Bayer on reducing unit costs, allowing gross margin to assess the company's transition toward a high-margin monetization model.